Methodology
Molecular
Test Description

Bi-directional sequencing of NRAS exon 4 is performed using PCR primers designed to target hotspot mutations in codons 117 and 146, among other regions in exon 4. Testing is available separately or in combination with BRAF, KRAS and HRAS in the RAS/RAF Panel. Testing is approved for specimens from the state of New York.

Clinical Significance

NRAS is highly homologous with KRAS; both are members of the most frequently mutated family of oncogenes. NRAS Mutations are found in a wide variety of solid tumors, in advanced systemic mastocytosis, and in myeloid neoplasias. Mutations in codon 117 and 146 are also believed to have similar effects as other mutations in RAS that involve exons 2 and 3. Patients with any known KRAS mutation or NRAS mutation may be resistant to certain tyrosine kinase inhibitors.

Specimen Requirements

FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. All slides can be packed at room temperature.

CPT Code(s)*
81403x1
Turnaround Time

7 days

Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.